Edition:
United Kingdom

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

8.60USD
12 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.60
Open
$8.55
Day's High
$8.90
Day's Low
$8.45
Volume
96,337
Avg. Vol
137,668
52-wk High
$29.35
52-wk Low
$8.07

Chart for

About

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab... (more)

Overall

Beta: --
Market Cap(Mil.): $695.75
Shares Outstanding(Mil.): 51.35
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM

08 Dec 2017

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares

14 Nov 2017

BRIEF-Coherus Biosciences Q3 loss per share $1.09

* Coherus Biosciences reports third quarter 2017 operating and financial results

06 Nov 2017

BRIEF-Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​

* Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing Source text: (http://bit.ly/2xYarNR) Further company coverage:

22 Sep 2017

BRIEF-‍Temasek Holdings reports 11.32 pct passive stake in Coherus Biosciences

* ‍Temasek Holdings (private) Ltd​ reports 11.32 pct passive stake in Coherus Biosciences Inc as of Aug 24 - sec filing Source text - http://bit.ly/2esXsfi Further company coverage:

31 Aug 2017

BRIEF-Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects

* Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects

28 Aug 2017

BRIEF-Coherus secures private placement from Temasek

* Coherus Biosciences Inc - ‍Temasek plans to invest up to $150 million over two tranches​

21 Aug 2017

BRIEF-Coherus Biosciences Q2 loss $1.08 per share

* Anticipate resubmitting BLA in U.S. At end of Q4 of 2017 for CHS-1701

07 Aug 2017

BRIEF-Coherus Biosciences says completed restructuring plan to reduce operating costs

* Says commenced and completed, a restructuring plan to reduce operating costs and better align its workforce

27 Jun 2017

BRIEF-Coherus Biosciences says projected filing timing for CHS-1420 biologics license application pushed to first half of 2018

* Coherus Biosciences - determined it is prudent to put into place alternative fill & finish vendor to support co's adalimumab biosimilar candidate chs-1420's bla filing

26 Jun 2017

Earnings vs. Estimates